CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 108 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,058,712 | -61.2% | 553,307 | -69.1% | 0.59% | -51.0% |
| Q1 2023 | $15,609,698 | +10.6% | 1,790,103 | -20.5% | 1.20% | +30.7% |
| Q4 2022 | $14,111,005 | +62.9% | 2,250,559 | -9.1% | 0.92% | +63.4% |
| Q3 2022 | $8,661,000 | +11.0% | 2,474,659 | -6.4% | 0.56% | +43.2% |
| Q2 2022 | $7,801,000 | +32.4% | 2,644,306 | +39.6% | 0.39% | +49.8% |
| Q1 2022 | $5,890,000 | -12.9% | 1,893,997 | -5.3% | 0.26% | +9.7% |
| Q4 2021 | $6,760,000 | – | 2,000,142 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |